Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics
about
Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesAnticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics.Characterization of patients with atrial fibrillation not treated with oral anticoagulantsAssociation between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review.The state of point-of-care testing: a European perspective.Impact of regular physical activity on weekly warfarin dose requirement.Who receives anticoagulant treatment with warfarin and why? A population-based study in Finland.Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.Are the risk factors listed in warfarin prescribing information associated with anticoagulation-related bleeding? A systematic literature review.Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage.Gastrointestinal bleeding and intracranial hemorrhage in concomitant users of warfarin and antihyperlipidemics.Telemedicine improves the monitoring process in anticoagulant treatment.Dedicated warfarin care programme results in superior warfarin control in Queensland, Australia.Point-of-care monitoring of warfarin treatment in community dwelling elderly--A randomised controlled study.Warfarin persistence among atrial fibrillation patients - why is treatment ended?Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers.Von Willebrand factor predicts major bleeding and mortality during oral anticoagulant treatment
P2860
Q24632951-36EDBD43-1342-4395-8471-BA509BBDB5BFQ34187660-51BFE1C6-FB8F-4CE0-99C3-6BA4DF7FA879Q34622896-1B34E00A-AF24-4966-91AB-DD98CFB1F908Q34781621-F2C3B292-88F3-4DBB-AB13-D0AEA0723C93Q35016262-1A62BD5D-AC77-455F-B069-F45F597E1250Q35308787-B53CB120-DABA-4C1F-AC90-76C85EB1FFB6Q35735988-0286E4BC-4100-4E67-9076-54FD972D1C21Q36241151-1AE9BFCB-FCC5-45B7-9388-BA09CB6F4BF9Q37454438-3997B316-A07F-45FF-AEC9-62117D6EFCAAQ37890023-A82DCE32-4D9C-4A1B-BD68-6EE2EEE08AC1Q38042441-C2B64A2A-E36D-4E00-9010-DD0A0ED912EFQ38236837-110304F4-CBF5-4262-BFF9-51523E474C63Q40456654-57FB3B2F-2947-437B-BA16-037EF94D66CAQ44721768-FDC412E8-88E2-429C-93CA-160979624289Q47189066-256A0F30-28E5-4353-99E9-D2B89AAEF003Q48046077-AA8266E4-8A2C-4916-8712-9AAEB70241C6Q51836770-6FB4DC2E-C510-4D16-94EA-D0CC66D2EF43Q53142338-CFF41822-C295-46E2-BA91-79E546620094Q57790828-25BB71D0-8A41-4E3A-9F05-94E0839B39AB
P2860
Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Bleeding complications during ...... d with anticoagulation clinics
@ast
Bleeding complications during ...... d with anticoagulation clinics
@en
type
label
Bleeding complications during ...... d with anticoagulation clinics
@ast
Bleeding complications during ...... d with anticoagulation clinics
@en
prefLabel
Bleeding complications during ...... d with anticoagulation clinics
@ast
Bleeding complications during ...... d with anticoagulation clinics
@en
P2093
P2860
P1476
Bleeding complications during ...... d with anticoagulation clinics
@en
P2093
Anders Själander
Jan-Håkan Jansson
Jonas Wallvik
Orjan Bjuhr
P2860
P304
P356
10.1080/02813430601183108
P577
2007-06-01T00:00:00Z